Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20017046 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL22058769 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL22059479 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23323248 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL21029771 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23332629 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL24936522 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23719677 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL20990354 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL19767510 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-11912993-B2 | Nucleic acid linked to a trivalent glycoconjugate | SILENCE THERAPEUTICS GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11873489-B2 | Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages | SILENCE THERAPEUTICS GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873489-B2 | Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages | SILENCE THERAPEUTICS GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11820971-B2 | Nucleic acids for inhibiting expression of PROS1 in a cell | Universität Bern (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11820971-B2 | Nucleic acids for inhibiting expression of PROS1 in a cell | Universität Bern (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20150315594-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-9163239-B2 | Compositions and methods for modulating apolipoprotein C-III expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9145558-B2 | Compositions and methods for modulating HBV expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912993-B2 | Nucleic acid linked to a trivalent glycoconjugate | RNASE1, DERA, SNRPE | ALDH1A1 923/4885THRB 1319/4885MAPK1 4702/4885 |
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | DPM1, XPO5, NISCH | ALDH1A1 1883/4885THRB 4818/4885MAPK1 2585/4885 |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | ALDH1A1 4609/4885THRB 3640/4885MAPK1 4423/4885 |
| US-11820971-B2 | Nucleic acids for inhibiting expression of PROS1 in a cell | RNASE1, SERBP1, PRSS8 | ALDH1A1 3980/4885THRB 2275/4885MAPK1 2423/4885 |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | ALDH1A1 3686/4885THRB 1298/4885MAPK1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.